Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 Next >
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Annual General Meeting of April 30, 2024
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.